CinCor Pharma sets IPO terms, as the biotech looks to raise up to $187 million
Marketwatch -

CinCor Pharma Inc. has set terms for its initial public offering, in which the Massachusetts-based biopharmaceutical company focusing on treatments of hypertension, could be valued at up to $602.1 million. The company could raise up to $187.0 million, as it is offering 11.0 million shares in the IPO, which is expected to price between $15 and $17 a share. The stock is expected to list on the Nasdaq under the ticker symbol "CINC." Morgan Stanley, Jefferies and Evercore ISI are the lead...

Read this story at

Loading...

Related Articles